Return to site

Congratulations to Our Customer for Published in Advanced Science (IF: 15)!

This study identifies (4S)-KEL12 as a promising ionizable lipid for mRNA delivery, showing higher efficacy and lower toxicity compared to existing options, with potential for cancer vaccine applications.

October 16, 2024

On Oct 10th, research team from RinuaGene Biotechnology Co. Ltd and Chinese Academy of Medical Sciences and Peking Union Medical College published a groundbreaking research paper titled "Discovery of Ketal-Ester Ionizable Lipid Nanoparticle with Reduced Hepatotoxicity, Enhanced Spleen Tropism for mRNA Vaccine Delivery" in the journal "Advanced Science" (impact factor: 15.1). 

In the quest to advance mRNA vaccine development, the safety and efficacy of lipid nanoparticle (LNP) delivery systems stand as pivotal factors. Researchers shine a spotlight on a new series of ketal ester lipids (KELs) that promise to reshape the landscape of mRNA vaccine delivery.

These KELs are engineered with a biodegradable ketal moiety in the linker and ester segments in the tail. Through rigorous iterative optimization, the researchers meticulously tuned the head and tail groups of these lipids to adjust their pKa and molecular shapes, identifying (4S)-KEL12 as a standout ionizable lipid for mRNA delivery.

(4S)-KEL12 LNPs outperformed the established DLin-MC3-DMA LNPs, delivering significantly higher efficacy and lower toxicity. When compared to SM-102 LNPs, (4S)-KEL12 LNPs exhibited superior spleen tropism, reduced liver tropism, and less hepatotoxicity. Moreover, these LNPs demonstrated impressive biodegradability following intramuscular or intravenous injection.

One of the most exciting findings was the robust cellular immune response elicited by (4S)-KEL12 LNPs encapsulated with a therapeutic mRNA cancer vaccine. This resulted in significant tumor regression and extended survival in tumor-bearing mice, underscoring the therapeutic potential of these LNPs.

 

 

In conjunction with the research study, peptides were synthesized by SBS Genetech. Since 2000, SBS Genetech has been at the forefront of providing solutions in life sciences. We offer safer, superior quality, and more cost-effective products to preeminent researchers in more than 60 countries, empowering them to make new discoveries in biology. Our products have been widely utilized in academic research, with results often published in leading academic journals like Science, Cell, Cancer Cell, and Cell Metabolism. We firmly believe that through continuous innovation and research, we will continually infuse new vitality and possibilities into the field of life sciences.